TABLE 1A.
Antigen-specific magnitude by vaccine group at Day of challenge (D0).
| Subclass | Antigen | Vaccine arm | Response rate | Median maga | Median maga range |
|---|---|---|---|---|---|
| IgG1 | ViBiot | Vi-PS | 23% (8/35) | 3.82E4 | 1.00E4–4.88E6 |
| Vi-TT | 76% (28/37) | 2.49E5 | 1.00E4–2.30E6 | ||
| TT | Vi-PS | 0% (0/35) | 2.60E5 | 5.30E4–5.72E6 | |
| Vi-TT | 68% (21/31) | 8.51E6 | 5.21E5–5.30E7 | ||
| IgG2 | ViBiot | Vi-PS | 29% (10/35) | 6.25E4 | 4.00E3–5.44E6 |
| Vi-TT | 46% (17/37) | 1.59E5 | 4.00E3–2.35E8 | ||
| TT | Vi-PS | 0% (0/35) | 4.00E3 | 4.00E3–4.19E4 | |
| Vi-TT | 16% (6/37) | 1.92E4 | 5.41E3–1.60E6 | ||
| IgG3 | ViBiot | Vi-PS | 31% (11/35) | 5.00E3 | 5.00E3–3.55 E6 |
| Vi-TT | 78% (29/37) | 1.31E4 | 5.00E3–3.17E5 | ||
| TT | Vi-PS | 0% (0/34) | 1.24E4 | 5.00E3–6.21E4 | |
| Vi-TT | 25% (9/36) | 3.60E4 | 1.61E4–5.64E5 | ||
| IgA | ViBiot | Vi-PS | 88% (30/34) | 4.71E5 | 2.43E4–5.78E6 |
| Vi-TT | 97% (36/37) | 1.05E6 | 9.78E4–1.86E7 | ||
| TT | Vi-PS | 0% (0/35) | 5.00E3 | 5.00E3–4.02E5 | |
| Vi-TT | 22% (8/37) | 1.01E5 | 5.00E3–9.83E5 |
a
Magnitude calculated as MFI*Dilution.